An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

BACKGROUND AND RATIONALE BORTEZOMIB: (PS-341, VELCADE®) is a selective inhibitor of the 26S proteasome, an integral component of the ubiquitinproteasome pathway. This phase II study evaluated the activity and tolerability of bortezomib in unresectable hepatocellular carcinoma (HCC) patients. METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, George P., Mahoney, Michelle R., Szydlo, Daniel, Mok, Tony S. K., Marshke, Robert, Holen, Kyle, Picus, Joel, Boyer, Michael, Pitot, Henry C., Rubin, Joseph, Philip, Philip A., Nowak, Anna, Wright, John J., Erlichman, Charles
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896232/
https://ncbi.nlm.nih.gov/pubmed/20839030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9532-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados